In this study the study team hypothesizes MR images will identify high-grade cancers
earlier and more frequently in men at high risk of developing prostate cancer. Subjects
will receive gadolinium (intravenous contrast agent) as part of their research MRI exam.
While the deposition of gadolinium (Gd) has been demonstrated in numerous studies, the
clinical consequences of Gd deposition are unknown. Gd enhanced MRI scans provide crucial
medical information regarding prostate and prostate cancer imaging and contrast-enhanced
images are a component of all guidelines and the PIRADS scoring system. The study team
will compare baseline prostate MR images of men at high risk of developing prostate
cancer to those without an identifiable predisposition and evaluate the role of a GRS in
screening men with at elevated risk of being diagnosed with prostate cancer.